Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In Vivo
Ovarian cancer is the most lethal gynecologic cancer in women. Its high mortality rate (68%) reflects the fact that 75% of patients have extensive (>stage III) disease at diagnosis and also the limited efficacy of currently available therapies. Consequently, there is clearly a great need to devel...
Main Authors: | Ramandeep Rattan, Rondell P. Graham, Jacie L. Maguire, Shailendra Giri, Viji Shridhar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2011-05-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558611800667 |
Similar Items
-
Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer.
by: Shailendra Giri, et al.
Published: (2013-01-01) -
Divergent Metabolic Effects of Metformin Merge to Enhance Eicosapentaenoic Acid Metabolism and Inhibit Ovarian Cancer In Vivo
by: Mary P. Udumula, et al.
Published: (2022-03-01) -
Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells
by: Sajad Dar, et al.
Published: (2017-08-01) -
Potentiation of Cisplatin Cytotoxicity in Resistant Ovarian Cancer SKOV3/Cisplatin Cells by Quercetin Pre-Treatment
by: Aseel Ali Hasan, et al.
Published: (2023-06-01) -
Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells.
by: Sham S Kakar, et al.
Published: (2014-01-01)